Ubs Group Ag Lucid Diagnostics Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.16 - $1.54 $222 - $295	192 Added 3.48%	5,708 $8,000
Q3 2023 Nov 09, 2023	BUY	$1.17 - $1.65 $6,453 - $9,101	5,516 New	5,516 $6,000
Q1 2023 May 12, 2023	SELL	$1.17 - $1.77 $1,178 - $1,782	-1,007 Reduced 28.25%	2,558 $3,000
Q4 2022 Feb 08, 2023	SELL	$1.21 - $2.27 $1,689 - $3,168	-1,396 Reduced 28.14%	3,565 $4,000
Q3 2022 Nov 10, 2022	BUY	$1.68 - $3.45 $628 - $1,290	374 Added 8.15%	4,961 $8,000

Q2 2022 Aug 10, 2022	BUY	$1.73 - $3.44 $5,368 - $10,674	3,103 Added 209.1%	4,587 $10,000
Q1 2022 May 16, 2022	SELL	$2.85 - $5.24 $1,151 - $2,116	-404 Reduced 21.4%	1,484 $5,000
Q4 2021 Feb 14, 2022	BUY	$4.87 - $11.76 $9,194 - $22,202	1,888 New	1,888 $10,000

2.15M

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $30.5M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.